PSEN1 and Alzheimer disease: In AD patients and 16- to 18-month-old APP/PS1 mice, a 10%–30% reduction of cerebral blood flow (CBF) and increased blood–brain barrier (BBB) permeability have been reported, which are considered potential biomarkers for predicting the progression and severity of AD [13–16].